ClinicalTrials.Veeva

Menu

Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.

E

Edward J. Holland

Status and phase

Completed
Phase 4

Conditions

Corneal Edema
Retinal Structural Change, Deposit and Degeneration
Cataracts
Visual Acuity Reduced Transiently

Treatments

Drug: Prednisolone acetate 1%
Drug: Difluprednate ophthalmic emulsion 0.05%

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01244334
SEMC 5/2009-011

Details and patient eligibility

About

The purpose of this clinical research study is to investigate the efficacy of predosing patients undergoing cataract surgery with the potent corticosteroid difluprednate ophthalmic emulsion 0.05% compared to prednisolone acetate 1% on corneal edema (swelling), and retinal thickness.

Enrollment

52 patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Healthy male or female 21 years of age or older
  • Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6-25 days between surgeries.
  • Willing and able to administer eye drops and record the times the drops were instilled
  • Understand and are willing to sign the Informed Consent form
  • Willing to complete the entire course of the study.

Exclusion criteria

  • Use of an eye medication or drops within 48 hours of the scheduled cataract surgery, other than the study medication or procedural solution required for surgery.
  • Known sensitivity to any of the ingredients in the study medications or similar medications.
  • Scheduled for 2nd eye cataract surgery earlier than 6 days or longer than 25 days apart.
  • Corneal edema in either eye.
  • Need for regional or general anesthesia during surgery.
  • Complicated cataract surgery, including use of iris hooks or iris stretchers.
  • Sight better than 20/100 in only one eye.
  • A history of previous intraocular surgery in either eye.
  • A history of uveitis, iritis, or intraocular inflammation.
  • Macular pathology of the retina.
  • Presence of glaucoma.
  • Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease.
  • History of steroid-related intraocular pressure (IOP) rise in the study eye.
  • Lack of an intact corneal epithelium.
  • Pupils that do not dilate to more than 5 mm prior to surgery or you require mechanical stretching of your pupil.
  • Diabetes mellitus.
  • Required use of a systemic steroidal or non-steroidal anti-inflammatory during the study period.
  • Doctor has determined the presence of a condition (i.e., UNCONTROLLED systemic disease) or a situation that may put the subject at significant risk, confound the study results or may interfere significantly with your participation in the study.
  • Females, who are pregnant, nursing an infant or planning a pregnancy.
  • Currently involved in another investigational study or have participated in one within the 30 days prior to entering this study.
  • Unable or unwilling to give signed informed consent prior to participation in any study-related procedures.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

52 participants in 2 patient groups

Difluprednate Ophthalmic Emulsion 0.05%
Active Comparator group
Treatment:
Drug: Difluprednate ophthalmic emulsion 0.05%
Prednisolone acetate suspension 0.1%
Active Comparator group
Treatment:
Drug: Prednisolone acetate 1%

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems